Interactions between proteins and platinum-containing anti-cancer drugs

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 214-224

  Bischin, Cristina ^a   Lupan, Alexandru ^a   Taciuc, Vicentiu ^a   Silaghi Dumitrescu, Radu ^a  

^a BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

Adduct; Cisplatin; Cysteine; Methionine; Resistance; Toxicity

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CARBOPLATIN; CISPLATIN; COPPER TRANSPORTER 1; CYTOCHROME C; DNA TOPOISOMERASE (ATP HYDROLYSING); FILAMIN; GLUTATHIONE; HEMOGLOBIN; LOBAPLATIN; METALLOPROTEINASE; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYOGLOBIN; NEDAPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; SERUM ALBUMIN; THIOREDOXIN; THIOREDOXIN REDUCTASE; TRANSFERRIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; PROTEINS;

EID: 79953770711     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955711795049844     Document Type: Review

References (96)

1. Rosenberg, B. Noble metal complexes in cancer chemotherapy. Adv. Exp. Med. Biol., 1977, 91, 129-50.
2. Che, C.-M.; Siu, F.M. Metal complexes in medicine with a focus on enzyme inhibition. Curr. Opin. Chem. Biol., 2010, 14, 255-261.
3. Cossa, G.; Gatti, L.; Zunino, F.; Perego, P. Strategies to improve the efficacy of platinum compounds. Curr. Med. Chem., 2009, 16(19), 2355-65.
4. Cullen, K.J.; Yang, Z.; Schumaker, L.; Guo, Z. Mitocondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr., 2007, 39, 43-50.
5. Hagrman, D.; Goodisman, J.; A-K., S. Kinetic study of the reaction of cisplatin with glutathion. J. Pharmacol. Exp. Ther., 2004, 308(2), 658-666.
6. Dabrowiak, J.K.; Goodisman, J.; Soid, A.-K. Kinetic study of the reaction of cisplatin with thiols. Drug. Metab. Rev., 2002, 30(12), 1378-1384.
7. Nagai, N.; Okuda, R.; Kinochita, M.; Ogata, H. Decomposition kinetics of cisplatin in human biological fluids. J. Pharm. Pharmacol., 1996, 48, 918-924.
8. Riley, C.M.; Sternson, L.A.; Repta, A.J.; Slyter, S.A. Monitoring the reactions of cisplatin with nucleotides and methionine by reversed-phase high-performance liquid chromatography using cationic and anionic pairing ions. Anal. Biochem., 1983, 130, 203-214.
9. Teuben, J.-M.; van Boom, S.S.G.E.; Reedijk, J. Intamolecular migration of co-ordinated platinum from a sulfur to N7 in the nucleopeptide Met-d(TpG)(5'-O-methioninate-N-ylcarbonyltymidine 2'-deoxiguanosine momophosphate. J. Chem. Soc. Dalton Trans., 1997, 3979-3980.
10. Chen, Y.; Guo, Z.; Mudoch, P.S.; Zang, E.; Sadler, P.J. Interconversion between S-and N-bound L/methionie adducts of Pt(dien)2+ (dien= diethylenetriamine) via dien ring-opened intermediates. J. Chem. Soc., Dalton Trans., 1998, 1503-1508.
11. Anderson, M.E.; Naganuma, A.; Meister, A. Protection against cisplatin toxicity by administration of glutathione. FASEB J., 1990, 4, 3251-3255.
12. Casciniu, S.; Cordella, L.; Del Ferro, E.; Fronzoni, M.; Catalano, G. Neuroprotective effect of reduced glutathione on cisplatin based chemotherapy in advanced gastric cancer: a randomized doubleblind placebo-controlled trial. J. Clin. Oncol., 1995, 13, 26-32.
13. Jenderny, S.; Lin, H.; Garrett, T.; Tew, K.D.; Townsend, D.M. Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity. Biomed. Pharmacother., 2010, 64, 73-76.
14. Petrovic, D.; Stojimirovic, B.; Petrovic, B.; Bugarcic, Z.M.; Bugarcic, Z.D. Studies of interactions between platinum (II) complexes and some biologically relevant molecules. Bioorg. Med. Chem., 2007, 15, 4203-4211.
15. Komiya, S.; Gebhardt, M.C.; Mangham, D.C.; Inoue, A. Role of glutathione in cisplatin resistance in osteosarcoma cell lines. J. Orthop. Res., 1998, 16, 15-22.
16. Prasad, S.B.; Rosangkima, G.; Khynriam, D. Cisplatin-induced toxicological effects in relation to the endogenous tissue glutathione level in tumor bearing mice. Asian J. Exp. Sci., 2006, 20(1), 55-68.
17. Schwartz, M.A.; Lazo, J.S.; Yallowich, J.C.; Reynolds, I.; Kagan, V.E.; Tyurin, V.; Kim, Y.A.; Watkins, S.C.; Pitt, B.R. Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tertbutyl hydroperoxide toxicity. J. Biol. Chem., 1994, 269, 15238-43.
18. Rojas, P.; Rios, C. Metalollothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine neurotoxicity in mice. Neurochem. Res., 1997, 22, 17-22.
19. Murphy, B.J.; Laderoute, K.R.; Chin, R.J.; Suttherland, R.M. Metallothionein II A is up-regulated by hipoxya in human A431 squamous carcinoma cells. Cancer. Res., 1994, 54, 5808-10.
20. Hagrman, D.; Goodisman, J.; Dabrowiak, J., C.; Abdul-Kader, S. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab. Dispos., 2003, 31(7), 916-923.
21. Kondo, Y.; Woo, E.S.; Michalska, A.E.; Andy Cho, K.H.; Lazo, J.S. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res., 1995, 55, 2021.
22. Kasahara, K.; Y., F.; Nishio, K.; Ohmori, T.; Sugimoto, Y.; Komiya, K.; T., M.; Saijo, N. Metallotionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 1991, 51, 3237-3242.
23. Saga, Y.; Hashimoto, H.; Yachiku, S.; T., I.; Tokumitsu, M. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int. J. Urol., 2004, 11(6), 407-15.
24. Wang, X.; Guo, Z. The role of sulfur in Platinum Anticancer Chemotherapy. Anti Cancer Agents Med. Chem., 2007, 7, 19-34.
25. Zhao, Y.Y.; Mandal, R.; Li, X.F. Intact human holo-transferrin interaction with oxaliplatin. Rapid. Commun. Mass. Spectrom., 2005, 19, 1956-1962.
26. Hoshino, T.; Misaki, M.; Yamamoto, M.; Schmitz, H.; Y, O.; Toguchi, H. Receptor-binding, in vitro cytotoxicity, and in vivo distribution of transferring-bound cis-platinum (II) of differing molar ratios. J. Control. Release, 1995, 75-81.
27. Berners-Price, S.J.; Ronconi, L.; P.J., S. Insight into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Prog. Nucl. Magn. Reson., 2006, 49, 65-98.
28. Hartinger, C.G.; Ang, W.H.; Casini, A.; Messori, L.; Keppler, B.K.; Dyson, J. Mass Spectrometric Analysis of Ubiquitin-Platinum Interacations of Leading Anticancer Drugs: MALDY versus ESI;. J. Anal. Atomic Spectrosc., 2007, 22(8), 960-967.
29. Isoe, T.; Naito, M.; A., S.; Hirai, R.; Tsuruo, T. Inhibition of different steps of the ubiquitin sysem by cisplatin and aclarubicin. Biochim. Biophys. Acta, 1992, 1117(2), 131-135.
30. Niture, S.K.; C.S., V.; Srivenugopal, K.S. Anticancer platinum drugs inhibit ubiquitin (ub)-dependent ptrotelysis through Sglutatyionilasion of ub-E1 and proteasome enzymes. Proc. Am. Assoc. Cancer Res., 2006, 47.
31. Yamada, M.; Tomida, A.; Yoshikawa, H.; Taketani, Y.; Tsuruo, T. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines. Cancer Chemother. Pharmacol., 1997, 40, 31-37.
32. Yokomizo, A. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomizcin c, doxorubicin, and etoposide. Cancer Res., 1995, 55, 4293-4296.
33. Witte, A.B.; K., A.; E., J.; H., E.; Arner, E.S.J. Inhibition of thioredoxin reductase but not glutathion reductase by the major classes of alkylating and platinum-containg anticancer compounds. Free. Radic. Biol. Med., 2005, 39, 696-703.
34. Chintala, S.K.; Ali-Osman, F.; Mohanam, S.; Rayford, A.; Go, Y.; Gokaslan, Z.L.; Gagercas, E.; Venkaiah, B.; Sawaya, R.; Nicolson, G.L.; Rao, J.S. Effects of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro. Clin. Exp. Metastasis, 1997, 15, 361-7.
35. Mandal, R.; Sawyer, M.B.; Li, X.F. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun. Mass Spectrom., 2006, 20, 2533-2538.
36. Mandal, R.; Teixeira, C.; Li, X.-F. Studies of cisplatin and hemoglobin interaction using nanospray mass spectrometry and liquid chromatography with inductively-coupled plasma mass spectrometry. Analyst, 2003, 128, 629-634.
37. Mandal, R.; R., K.; Li, X.-F. Interaction of oxaliplatin, cisplatin and carboplatin with Hemoglobin and the resulting release of a hem group. Chem. Res. Toxicol., 2004, 17, 1391-1397.
38. Peng, J.; Mandal, R.; Sawyer, M.; Li, X.-F. Characterization of intact hemoglobin and oxaliplatin interaction by nanoelectrospray ionization tandem mass spectrometry. Clin. Chem., 2005, 51(12), 2274-2281.
39. Silaghi-Dumitrescu, R.; Reeder, B.J.; Nicholls, P.; Cooper, C.E.; Wilson, M.T. Ferryl haem protonation gates peroxidatic reactivity in globins. Biochem. J., 2007, 403(3), 391-5.
40. Vollaard, N.B.; Shearman, J.P.; Cooper, C.E. Exercise-induced oxidative stress:myths, realities and physiological relevance. Sports Med., 2005, 35(12), 1045-62.
41. Vollaard, N.B.; Reeder, B.J.; Shearman, J.P.; Menu, P.; Wilson, M.T.; Cooper, C.E. A new sensitive assay reveals that hemoglobin is oxidatively modified in vivo. Free Radic. Biol. Med., 2005, 39(9), 1216-28.
42. Reeder, B.J.; Svistunenko, D.A.; Cooper, C.E.; Wilson, M.T. The radical and redox chemistry of myoglobin and hemoglobin: from in vitro studies to human pathology. Antioxid. Redox. Signal., 2004, 6(6), 954-966.
43. Taciuc, V.; Bischin, C.; Silaghi-Dumitrescu, R. A novel mechanism for platinum-based drugs: cisplatin and related compounds as prooxidants in blood; Silaghi-Dumitrescu, R. and Garban, G., Ed.; Cluj University Press: Cluj-Napoca, Romania, 2009, pp 130-134.
44. Pendyal, L.; Creaven, P.J. In vitro citotoxicity, protein binding reed blood cell partitioning and biotransformation of oxaliplatin. Cancer. Res., 1993, 53, 5970-6.
45. Zao, T.; King, F.L. A mass spectrometric comparision of the interactions of cisplatin and transplatin with myoglobin. J. Inorg. Biochem., 2010, 104, 186-192.
46. Ivanov, A.I.; Christodoulou, J.; Parkinson, J.A.; Barnham, K.J.; A., T.; Woodrow, J.; Sadler, P.J. Cisplatin binding sites on human albumin. J. Biol. Chem., 1998, 273(24), 14721-14730.
47. Lemna, T.; Pawliszyn, J. Human serum albumin interaction with oxaliplatin studied by caplillary isoelectric focusing with the whole column imaging detection. J. Pharm. Biomed. Anal., 2009, 50, 570-575.
48. Yue, Y.; Chen, X.; Qin, J.; Yao, X. Spectroscopic investigation on the binding of antineoplastic drug oxaliplatin to human serum albumin and molecular modeling. Colloids Surfaces B, 2009, 69, 51-57.
49. Trynda-Lemiesz, L.; Luczkowski, M. Human serum albumin: spectroscopies studies of the paclitaxel binding and proximity relationship with cisplatin and adriamycin. J. Inorg. Biochem., 2004, 98, 1851-1856.
50. Timerbaev, A.R.; Aleksenko, S.S.; Polec-Pawlak, K.; Ruzik, R.; Semenova, O.; Hartinger, C.G.; Oszwalddowski, S.; Galanski, M.; Jarosz, M.; Keppler, B.K. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma mass spectrometry: characterization of interaction between Pt(II) complexes and human serum albumin. Electrophoresis, 2004, 25, 1988-1995.
51. Aleksenco, S.S.; Hartinger, C.G.; Semenova, O.; Meelich, K.; Timerbaev, A.R.; Keppler, B.K. Characterization of interaction between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. J. Cromatogr., 2007, 1155, 218-221.
52. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release., 2008, 132, 171-183.
53. Oettl, K.; Stauber, R.E. Physiological and pathological changes in the redox state of HSA. Br. J. Pharm., 2007, 151, 580-590.
54. Yoshiyama, Y.; Yamaguchi, K.; Matsuo, K.; Kurokawa, M.; Kanke, M. The effect of fosfomycin on nedaplatin-induced neprothoxicity in rats. J. Infect. Chemother., 2005, 11, 14-17.
55. Mross, K.; Meyberg, F.; Fiebig, H.H.; Hamm, K.; Hieber, U.; Aulenbacher, P.; Hossfeld, D.K. Pharmacokinetic and pharmacodynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie, 1992, 15, 139-146.
56. Kagan, V.E.; Borisenko, G.G.; Tyurina, Y.Y.; Tyurin, V.A.; Jiang, J.; Potapovich, A.I.; Kini, V.; Amoscato, A.A.; Fujii, Y. Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radic. Biol. Med., 2004, 37(12), 1963-85.
57. Kagan, V.E.; Tyurin, V.A.; Jiang, J.; Tyurina, Y.Y.; Ritov, V.B.; Amoscato, A.A.; Osipov, A.N.; Belikova, N.A.; Kapralov, A.A.; Kini, V.; Vlasova, II; Zhao, Q.; Zou, M.; Di, P.; Svistunenko, D.A.; Kurnikov, I.V.; Borisenko, G.G. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol., 2005, 1(4), 223-32.
58. Kagan, V.E.; Bayir, H.A.; Belikova, N.A.; Kapralov, O.; Tyurina, Y.Y.; Tyurin, V.A.; Jiang, J.; Stoyanovsky, D.A.; Wipf, P.; Kochanek, P.M.; Greenberger, J.S.; Pitt, B.; Shvedova, A.A.; Borisenko, G. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic. Biol. Med., 2009, 46(11), 1439-53.
59. Zhao, T.; King, F.L. Direct determination of the primary binding site of cisplatin on cytochrome c by mass spectrometry. J. Am. Soc. Mass. Spectrom., 2009, 20, 1141-1149.
60. Gabbiani, C.; Casini, A.; Mastrobuoni, G.; Kirshenbaum, N.; Moshel, O.; Pieraccini, G.; Moneti, G.; Messori, L.; Gibson, D. Peculiar mechanistic and structural features of the carboplatincytochrome c system revealed by ESI-MS analysis. J. Biol. Inorg. Chem., 2008, 13(5), 755-64.
61. Yang, G.; Miao, R.; Chen, J.; Mey, Y.; Tang, H.; Hong, J.; Guo, Z.; Longgen, Z. Determination of binding sites in carboplatin-bound cytochrome c using electrospray ionization mass spectrometry and tandem mass spectrometry. J. Mass. Spectrom., 2005, 40, 1005-1016.
62. Boswell, A.P.; Moore, G.R.; Williams, R.J.P. The binding of platinum complexes to tuna cytochrome c. Biochem. J., 1982, 201, 523-526.
63. Larson, A.C.; Adams, P.L.; Jandial, D.D.; Blair, B.G.; Safaei, R.; Howel, S.B. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem. Pharmacol., 2010, 80, 448-454.
64. Dolgova, N.V.; Olson, D.; Lutsenko, S.; Dmitriev, O.Y. The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin. Biochem. J., 2009, 419(1), 51-6.
65. Arnesano, F.; Natile, G. "Platinum on the road": Interactions of antitumoral cisplatin with proteins. Pure Appl. Chem., 2008, 80, 2715-2725.
66. Liang, X.-J.; Shen, D.-W.; Garfield, S.; Gottesman, M.M. Mislicalisation of Membrane Proteins Associated with Multidrug Resistance in Cisplatin-resistant Cancer Cell Lines. Cancer Res., 2003, 63, 5909-5916.
67. Shen, D.-W.; Liag., X.-J.; Gawinowicz., M.A.; Gottesman., M.M. Identification of cytoskeletal [14C] Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. Mol. Pharmacol., 2004, 66, 789-793.
68. Holm, R.H.; Kennepohl, P.; Solomon, E.I. Structural and Functional Aspects of Metal Sites in Biology. Chem. Rev., 1996, 96(7), 2239-2314.
69. Davies, D.R.; Braam, L.M.; Reznikoff, W.S.; Rayment, I. Threedimensional structure of a TN5-transposase-related proteins determined at 2.9-A resolution. J. Biol. Chem., 1999, 274, 11904-11913.
70. Gorman, M.A.; Morera, S.; Rothwell, D.G.; de La Fortelle, E.; Mol, C.D.; Tainer, J.A.; Hickson, I.D.; Freemont, P.S. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. EMBO J., 1997, 16, 6548-6558.
71. Diez, J.; Diederichs, K.; Greller, G.; Horlacher, R.; Boos, W.; Welte, W. The crystal structure of a liganded trehalose/maltosebinding protein from the hyperthermophilic Archaeon Thermococcus litoralis at 1.85 A. J. Mol. Biol., 2001, 305, 905-915.
72. Schubot, F.D.; Kataeva, I.A.; Blum, D.L.; Shah, A.K.; Ljungdahl, L.G.; Rose, J.P.; Wang, B.C. Structural basis for the substrate specificity of the feruloyl esterase domain of the cellulosomal xylanase Z from Clostridium thermocellum. Biochem. Biophys. Res. Commun., 2001, 40, 12524-12532.
73. Gu, Y.; Reshetnikova, L.; Li, Y.; Wu, Y.; Yan, H.; Singh, S.; Ji, X. Crystal structure of shikimate kinase from Mycobacterium tuberculosis reveals the dynamic role of the LID domain in catalysis. J. Mol. Biol., 2002, 319, 779-789.
74. Zeth, K.; Ravelli, R.B.; Paal, K.; Cusack, S.; Bukau, B.; Dougan, D.A. Structural analysis of the adaptor protein ClpS in complex with the N-terminal domain of ClpA. Nat. Struct. Biol., 2002, 9, 906-911.
75. Garrett, T.P.J.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Zhu, H.-J.; Walker, F.; Frenkel, M.J.; Hoyne, P.A.; Jorissen, R.N.; Nice, E.C.; Burgess, A.W.; Ward, C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell, 2002, 110, 763-773.
76. Fernandez-Tornero, C.; Lopez, R.; Garcia, E.; Gimenez-Gallego, G.; Romero, A. A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat. Struct. Biol., 2001, 8, 1020-1024.
77. Lukacik, P.; Roversi, P.; White, J.; Esser, D.; Smith, G.P.; Billington, J.; Williams, P.A.; Rudd, P.M.; Wormald, M.R.; Harvey, D.J.; Crispin, M.D.M.; Radcliffe, C.M.; Dwek, R.A.; Evans, D.J.; Morgan, B.P.; Smith, R.A.G.; Lea, S.M. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl. Acad. Sci., 2004, 101, 1279-1284.
78. Vogt, J.; Schulz, G.E. The structure of the outer membrane protein OmpX from Escherichia coli reveals possible mechanisms of virulence. Structure, 1999, 7, 1301-1309.
79. Lee, S.; Sowa, M.E.; Watanabe, Y.; Sigler, P.B.; Chiu, W.; Yoshida, M.; Tsai, F.T.F. The structure of ClpB: a molecular chaperone that rescues proteins from an aggregated state. Cell, 2003, 115, 229-240.
80. Varughese, K.I.; Ruggeri, Z.M.; Celikel, R. Platinum-induced space-group transformation in crystals of the platelet glycoprotein Ib alpha N-terminal domain. Acta Crystallogr. Sect. D, 2004, 60, 405-411.
81. Patel, S.D.; Rajala, M.W.; Rossetti, L.; Scherer, P.E.; Shapiro, L. Disulfide-dependent multimeric assembly of resistin family hormones. Science, 2004, 304, 1154-1158.
82. Baikalov, I.; Schroder, I.; Kaczor-Grzeskowiak, M.; Grzeskowiak, K.; Gunsalus, R.P.; Dickerson, R.E. Structure of the Escherichia coli response regulator NarL. Biochemistry, 1996, 35, 11053-11061.
83. Kumaraswami, M.; Howe, M.M.; Park, H.W. Crystal structure of the Mor protein of bacteriophage Mu, a member of the Mor/C family of transcription activators. J. Biol. Chem., 2004, 279, 16581-16590.
84. Papagrigoriou, E.; Gingras, A.R.; Barsukov, I.L.; Bate, N.; Fillingham, I.J.; Patel, B.; Frank, R.; Ziegler, W.H.; Roberts, G.C.; Critchley, D.R.; Emsley, J. Activation of a vinculin-binding site in the talin rod involves rearrangement of a five-helix bundle. EMBO J., 2004, 23, 2942-2951.
85. Fujimoto, Z.; Kaneko, S.; Momma, M.; Kobayashi, H.; Mizuno, H. Crystal structure of rice alpha-galactosidase complexed with Dgalactose. J. Biol. Chem., 2003, 278, 20313-20318.
86. Pedersen, L.; Henriksen, A. Acyl-CoA oxidase 1 from Arabidopsis thaliana. Structure of a key enzyme in plant lipid metabolism. J. Mol. Biol., 2005, 345, 487-500.
87. Locher, M.; Lehnert, B.; Krauss, K.; Heesemann, J.; Groll, M.; Wilharm, G. Crystal structure of the Yersinia enterocolitica type III secretion chaperone SycT. J. Biol. Chem., 2005, 280, 31149-31155.
88. Tarbouriech, N.; Ruggiero, F.; Deturenne-Tessier, M.; Ooka, T.; Burmeister, W.P. Structure of the Epstein-Barr virus oncogene BARF1. J. Mol. Biol., 2006, 359, 667-668.
89. Goto, T.; Abe, Y.; Kakuta, Y.; Takeshita, K.; Imoto, T.; Ueda, T. Crystal structure of Tapes japonica Lysozyme with substrate analogue: structural basis of the catalytic mechanism and manifestation of its chitinase activity accompanied by quaternary structural change. J. Biol. Chem., 2007, 282, 27459-27467.
90. Casini, A.; Mastrobuoni, G.; Temperini, C.; Gabbiani, C.; Francese, S.; Moneti, G.; Supuran, C.T.; Scozzafava, A.; Messori, L. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem. Commun., 2007, 156-158.
91. Yang, X.; Zhou, J.; Sun, L.; Wei, Z.; Gao, J.; Gong, W.; Xu, R.M.; Rao, Z.; Liu, Y. Structural basis for the function of DCN-1 in protein Neddylation. J. Biol. Chem., 2007, 282, 24490-24494.
92. Bachhawat, P.; Stock, A.M. Crystal structures of the receiver domain of the response regulator PhoP from Escherichia coli in the absence and presence of the phosphoryl analog beryllofluoride. J. Bacteriol., 2007, 189, 5987-5995.
93. Martinez, M.A.; Zaballa, M.E.; Schaeffer, F.; Bellinzoni, M.; Albanesi, D.; Schujman, G.E.; Vila, A.J.; Alzari, P.M.; De Mendoza, D. A novel role of malonyl-ACP in lipid homeostasis. Biochemistry, 2010, 49, 3161-3167.
94. Angkawidjaja, C.; You, D.J.; Matsumura, H.; Kuwahara, K.; Koga, Y.; Takano, K.; Kanaya, S. Crystal structure of a family I.3 lipase from Pseudomonas sp. MIS38 in a closed conformation. FEBS Lett., 2007, 581, 5060-5064.
95. Lo, Y.C.; Ko, T.P.; Su, W.C.; Su, T.L.; Wang, A.H.J. Terpyridineplatinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1. J. Inorg. Biochem., 2009, 103, 1082-1092.
96. Boal, A.K.; Rosenzweig, A.C. Crystal structures of cisplatin bound to a human copper chaperone. J. Am. Chem. Soc., 2009, 131, 14196-14197.